Combination chemotherapy and immunotherapy regimen
This page covers all Combination chemotherapy and immunotherapy regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD20 (rituximab), proteasome (bortezomib), DNA alkylation (cyclophosphamide), glucocorticoid receptor (dexamethasone).
Targets
Phase 3 pipeline (2)
- M-VTD-PACE · University of Arkansas · Oncology
M-VTD-PACE is a combination chemotherapy and immunotherapy regimen that uses multiple agents to target and kill multiple myeloma cells through different mechanisms. - Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib · University of Ulm · Oncology
This combination regimen uses a corticosteroid, B-cell depleting antibody, alkylating agent, and proteasome inhibitor to suppress immune cells and induce apoptosis in malignant plasma cells.
Patent intelligence
- combination chemotherapy and immunotherapy regimen patent landscape — aggregated cliff calendar, attackable patents, originator estates